Bio-Rad Laboratories
BIO
#1792
Rank
โ‚ฌ8.74 B
Marketcap
310,41ย โ‚ฌ
Share price
0.58%
Change (1 day)
11.58%
Change (1 year)
Bio-Rad Laboratories, Inc. is an American manufacturer of products for the life science research and clinical diagnostics markets.

P/E ratio for Bio-Rad Laboratories (BIO)

P/E ratio as of November 2024 (TTM): -56.6

According to Bio-Rad Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -56.6372. At the end of 2022 the company had a P/E ratio of -3.47.

P/E ratio history for Bio-Rad Laboratories from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-3.47-165.53%
20215.3016.25%
20204.56-27.43%
20196.28-67.07%
201819.1-70.6%
201764.9-65.84%
2016190429.94%
201535.8-8.46%
201439.1-13.87%
201345.4159.13%
201217.516.5%
201115.1-2.88%
201015.5-15.16%
200918.3-19.95%
200822.8-23.36%
200729.841.45%
200621.10.69%
200520.9-3.43%
200421.612.62%
200319.234.12%
200214.3-18.94%
200117.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
15.0-126.43%๐Ÿ‡บ๐Ÿ‡ธ USA
33.5-159.22%๐Ÿ‡บ๐Ÿ‡ธ USA
40.5-171.58%๐Ÿ‡บ๐Ÿ‡ธ USA
34.4-160.71%๐Ÿ‡บ๐Ÿ‡ธ USA
11.0-119.49%๐Ÿ‡บ๐Ÿ‡ธ USA
29.2-151.55%๐Ÿ‡บ๐Ÿ‡ธ USA
21.0-137.09%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.